Today 11 Companies Raised Over $766 Million.
ReNAgade Therapeutics, Builder.ai, and TymeBank raised $300M, $250M, and $77.8M.
Interested in human due diligence services for your investment firm? Visit our website to learn more and connect with us today!
Deal #1: Twirl, Stockholm's Innovator in Data Infrastructure, Secures $2.5M Pre-Seed Funding.
About:
Twirl, a revolutionary platform based in Stockholm, empowers data teams to focus on creating value instead of getting bogged down with tooling. This innovative platform efficiently manages data pipeline deployment, infrastructure, and scaling. Twirl takes pride in being a code-first enterprise, adeptly integrating analytics, machine learning, and more.
Funding Round Info:
Twirl recently netted $2.5 million in a pre-seed round to disrupt the data infrastructure status quo. These funds will be utilized to expand the team and accelerate customer onboarding. This successful round was spearheaded by Creandum, and included contributions from Cocoa Ventures and various angel investors.
Deal #2: ReNAgade Therapeutics Scores Over $300M in Series A Funding to Revolutionize RNA Medicine.
About:
ReNAgade Therapeutics is pioneering RNA medicines' untapped potential, aiming to revolutionize disease treatment across the body. We have created a unique RNA delivery system integrated with a comprehensive RNA platform for coding, editing, and gene insertion. This approach develops novel medicines and propels the medical field into the future. Our dedicated team of experts is driving this shift with profound RNA and delivery knowledge.
Funding Round Info:
ReNAgade Therapeutics has raked in a whopping $300 million in a Series A financing round, led by MPM BioImpact and F2 Ventures. Leveraging proprietary delivery technologies, including innovative lipid nanoparticles (LNPs), we're addressing significant challenges in RNA therapeutics. Our mission is to deliver RNA medicines to previously unreachable body tissues and cells, significantly expanding the potential disease market. We've partnered with Orna Therapeutics to merge our delivery platform with their circular RNA technology. This collaboration paved the way for Orna's deal with Merck, which utilizes technologies developed under the Orna/ReNAgade joint venture.
Deal #3: Hydrogen Storage Pioneer Endua Lands $7.5M in Pre-Series Funding.
About:
Endua, a groundbreaking startup founded by Paul Sernia in 2021, is redefining renewable energy storage solutions. Our unique, modular hydrogen power banks can power remote communities, industries, and off-grid infrastructure round the clock. Capable of generating up to 100 kW per module, our power banks can efficiently power everything from water pumps to telecom infrastructure. Endua's innovative design stores excess renewable energy as hydrogen, converting it to electricity when required, offering scalable energy solutions.
Funding Round Info:
Endua announced a successful AU$11.8 million (approximately $7.8 million) funding round. New investors, Queensland Investment Corporation (QIC), Melt Ventures, and 77 Partners, collectively contributed AU$7.5 million. The remainder came from returning strategic investors Main Sequence, the deep tech fund founded by CSIRO, and Ampol, Australia's leading transport energy provider.
Deal #4: Larkspur Biosciences Secures $35.5M Financing, Pioneering Precision Immunotherapies to Defeat Cancer.
About:
Larkspur Biosciences is taking aim at the unique mechanisms cancer uses to manipulate the immune system. Founded by eminent scientists, Drs. Lewis Cantley, Nathanael Gray, and Vijay K. Kuchroo, Larkspur is developing precision immunotherapies, targeting genetically and immunologically distinct subtypes of colorectal cancer (CRC). Our strategy focuses on patients identifiable through biopsy whose T cells are present at the tumor, making them ideal candidates for the company's cutting-edge immunotherapy strategies.
Funding Round Info:
Larkspur Biosciences unveiled its launch, fortified by $35.5 million raised in combined seed and Series A funding. The round was led by Polaris Innovation Fund, 3E Bioventures Capital, and Takeda Ventures, Inc., and also saw participation from Creacion Ventures, Med-Fine Capital, and Cornell University. The funding will propel IND-enabling studies for Larkspur’s flagship program, which uses an innovative lipid remodeling approach to expose tumors. It will also boost preclinical studies for a pioneering program targeting Pin1, a critical mechanism for activating immune cells. Larkspur's LarkX discovery platform harnesses patient genetics and immune phenotypes to drive its robust pipeline and collaborations.
Deal #5: Ariadne Raises $7M in Series A Funding to Revolutionize Commercial Real Estate with Advanced Analytics.
About:
Ariadne is a trailblazer in people flow analytics, providing real-time insights for physical retail stores, shopping malls, airports, and smart cities. Our cutting-edge platform leverages smartphone signals to pinpoint exact locations and journeys with remarkable accuracy, up to 30cm. This innovative technology has various applications, from optimizing store layouts and testing signage effectiveness in real-time, to enhancing customer experience through strategic staff scheduling. Moreover, Ariadne's solution integrates with ERP, tracks conversions, manages workforce, and even provides targeted push notifications, transforming into a potent omnichannel marketing and navigation tool when shoppers opt-in, all while ensuring GDPR privacy.
Funding Round Info:
Ariadne, the German innovator in location data and crowd analytics, announced a successful $7 million Series A round. This round was led by returning investor Marathon Venture Capital and included strategic investment from Lamda Development, as well as contributions from both returning and new angel investors.
Deal #6: smartbax Nets €1.2M Seed Financing, Paving the Way for Next-Gen Antibiotics.
About:
smartbax is a pioneer in developing multi-targeted, antibacterial compounds that exhibit exceptional potency against multi-drug resistant bacteria and stubborn biofilms. Our product candidates operate via a unique dual-targeted mechanism, disrupting essential processes in resistant bacteria's energy metabolism while also stimulating protein secretion, causing the bacteria to self-destruct.
Funding Round Info:
smartbax announced the completion of a €1.2 million seed funding round, led by Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), raising the company's total capital to €1.9 million. This funding will expedite preclinical studies of smartbax's small molecule antibiotics, broaden its scientific team, and fuel the pursuit of innovative solutions against multi-drug resistant pathogens.
Deal #7: Amify Secures $10M in Series B Funding, Set to Enhance Its Amazon Optimization Services.
About:
As the pioneering Amazon-as-a-Service provider, Amify delivers top-tier services for brands to master their Amazon channel strategy. Serving as an outsourced Amazon team, we empower companies to dominate their brand presence on the world's largest ecommerce platform. We leverage cross-channel data to enhance sales and customer experience, with over $200M of goods sold on Amazon in 2021 under our management. Our breadth of expertise spans branding, advertising, data analytics, and business operations. We act as a seamless extension of our clients' teams, designing high-performing storefronts and optimized logistics to simplify their Amazon success.
Funding Round Info:
Amify, a leader in technology-driven Amazon optimization and advertising solutions, announced the completion of a $10 million Series B funding round. This round saw participation from strategic investors like Mercury Fund, Cincy Tech, and SAAS Ventures, as well as several undisclosed angel investors. This capital infusion will accelerate Amify's strategic edge in the e-commerce marketing landscape, improve our proprietary marketplace optimization platform, and bolster team expansion to meet the burgeoning demand in e-commerce marketplaces.
Deal #8: TymeBank, South Africa's Challenger Bank, Scoops Up $77.8M Funding from Norrsken22 and Blue Earth Capital.
About:
Helmed by CEO Coen Jonker, Tyme is a pioneering digital banking group committed to bridging the digital gap in emerging markets by integrating into physical retail ecosystems. The firm excels in designing, creating, and commercializing digital banks tailored to the mass market, especially targeting underserved and underbanked communities. Tyme takes a unique approach by creating effective financial education and cash management solutions for these markets, thereby tackling the challenges of digital banking head-on.
Funding Round Info:
Tyme, the Singapore-based digital banking group, has secured $77.8M in Series C funding. Investment heavyweights Norrsken22 and Blue Earth Capital led the round, joined by existing investor Tencent. The raised capital will be channeled to bolster operations in South Africa and the Philippines and pave the way for potential expansion in Southeast Asia.
Deal #9: Paydock Secures £25M Series A Funding from Silverstripe, Innovating Payment Orchestration.
About:
Paydock is revolutionizing payment orchestration, providing swift connectivity to fintech and payment systems for financial institutions and merchants without disrupting their existing infrastructure. Paydock's agnostic platform helps customers cut costs and mitigate risks associated with traditional multi-vendor payment solutions. It allows for 'plug-and-play' vendor integration and bolsters security. Noted for its bank-grade security, Paydock has become a sector standout with its auditable and traceable API stack.
Funding Round Info:
Paydock, the front-runner in pure-play orchestration platforms, announced a £25M Series A funding round led by Silverstripe Investment Management Limited.
Deal #10: Builder.ai Rakes in $250M in Series D Funding to Revolutionize App-Building Space.
About:
Builder.ai, powered by AI, is revolutionizing the software world with its platform that assists enterprises, small businesses, and individual entrepreneurs in building, running, and scaling their software. It offers this service without the need for coding expertise or extensive technical knowledge.
Funding Round Info:
Builder.ai announced securing $250 million in a Series D funding round, led by the Qatar Investment Authority (QIA), bringing its total funding to over $450 million. The round also saw participation from existing and new investors, including Iconiq Capital, Jungle Ventures, and Insight Partners. The company, boasting 2.3x revenue growth, now aims to leverage human conversation for app building on its platform, shifting away from the conventional "expert-heavy white-canvas systems" typical in the no-code/low-code space.
Deal #11: TISSIUM Bags €50M in Series D Round to Power Commercial Launch and Expand its Biopolymer Platform.
About:
TISSIUM, a MedTech company based in Paris and Boston, is transforming the way tissue repair and reconstruction are approached. TISSIUM's unique biopolymer platform is the bedrock of a diverse product portfolio, each designed to enhance tissue reconstruction in its unique way. From sutureless nerve repair and hernia repair to cardiovascular sealants, TISSIUM addresses unmet clinical needs. Co-founded in 2013 by MIT's Professor Robert Langer and Brigham and Women's Hospital's Professor Jeffrey M. Karp, TISSIUM's groundbreaking technology is based on stellar research and intellectual property.
Funding Round Info:
TISSIUM announced today the closing of a €50 million Series D round, with contributions from new and existing global investors, including Fonds Stratégique des Transitions managed by ISALT, Merieux Developpement, Cathay Health, Credit Mutuel Innovation, and Sofinnova Partners. The funding coincides with important milestones, including the first-in-human study on its nerve repair product, COAPTIUM Connect, in Australia. The funds will facilitate the commercialization of its first products in nerve and hernia repair and expand its product pipeline and platform. As TISSIUM extends its product reach, the company also plans to speed up international expansion and explore partnerships in select verticals.